End of the beginning and public health pharmacogenomics: Knowledge in 'Mode 2' and P5 Medicine

Current Pharmacogenomics and Personalized Medicine

Volumn 10, Issue 1, 2012, Pages 1-6

  Özdemir, Vural ^a   Fisher, Erik ^b   Dove, Edward S ^a   Burton, Hilary ^c   Wright, Galen E B ^d   Masellis, Mario ^e   Warnich, Louise ^d  

^a MCGILL UNIVERSITY   (Canada)

^b ARIZONA STATE UNIVERSITY   (United States)

^c PHG FOUNDATION   (United Kingdom)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Africa; Global personalized medicine; Knowledge in mode 2; Omics biotechnologies; P5 medicine; Public health pharmacogenomics; Science studies; Sociomateriality

Indexed keywords

CHINESE MEDICINE; EDITORIAL; GLIOBLASTOMA; HUMAN; NUTRIGENOMICS; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHARMACOGENOMICS; PUBLIC HEALTH; SOCIOECONOMICS;

EID: 84860294442     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/1875692111201010001     Document Type: Editorial

References (41)

1. Nowotny H, Scott P, Gibbons M. 'Mode 2' Revisited: The new production of knowledge. Minerva 2003; 41: 179-94.
2. Zimmern RL. Genomics and individuals in public health practice: are we luddites or can we meet the challenge? J Public Health (Oxf) 2011; 33(4): 477-82.
3. Motulsky AG. Drug reactions, enzymes and biochemical genetics. JAMA 1957; 165: 835-7.
4. Vogel F. Moderne problem der humangenetik. Ergeb Inn Med U Kinderheilk 1959; 12: 52-125.
5. Kalow W. Pharmacogenetics. Heredity and the Response to Drugs. Philadelphia: W.B. Saunders Co. 1962.
6. Schmeck HM. Heredity Linked to Drug Effects. New York Times, October 10, 1962.
7. Kalow W, Ozdemir V, Tang BK, et al. The science of pharmacological variability: an essay. Clin Pharmacol Ther 1999; 66(5): 445-7.
8. Masellis M. Pharmacogenetic analysis of serotonin receptors and clinical response to clozapine in schizophrenia patients. MSc Thesis, Toronto: University of Toronto 1997.
9. Dandara C, Adebamowo C, de Vries J, et al. An idea whose time has come? An African foresight observatory on genomics medicine and data-intensive global science. Curr Pharmacogenomics Person Med 2012; 10(1): 7-15.
10. Ozdemir V, Lerer B. Pharmacogenomics and the promise of personalized medicine. In: Pharmacogenomics, Second Edition. Kalow W, Meyer UA, Tyndale RF, Eds. New York: Francis and Taylor 2005; pp. 13-50.
11. Kalow W. Pharmacogenetics in perspective. Drug Metab Dispos 2001; 29(4 Pt 2): 468-70. Available from: http://dmd.aspetjournals. org/content/29/4/468.full.pdf [Accessed January 30, 2012].
12. Hedgecoe AM. Terminology and the construction of scientific disciplines: the case of pharmacogenomics. Sci Technol Human Values 2003; 28: 513-37.
13. Ozdemir V, Suarez-Kurtz G, Stenne R, et al. Risk assessment and communication tools for genotype associations with multifactorial phenotypes: The concept of 'edge effect' and cultivating an ethical bridge between omics innovations and society. OMICS 2009; 13(1): 43-62.
14. Reddy PJ, Jain R, Paik YK, et al. Personalized medicine in the age of pharmacoproteomics: A close up on India and need for social science engagement for responsible innovation in post-proteomic biology. Curr Pharmacogenomics Person Med 2011; 9(1): 67-75.
15. Warnich L, Drögemöller BI, Pepper MS, et al. Pharmacogenomic research in South Africa: Lessons learned and future opportunities in the rainbow nation. Curr Pharmacogenomics Person Med 2011; 9(3): 191-207.
16. Pashayan N, Duffy SW, Chowdhury S, et al. Polygenic susceptibility to prostate and breast cancer: implications for personalised screening: Polygenic risk and personalised cancer screening. Br J Cancer 2011; 104(10): 1656-63.
17. Ozdemir V, Muljono DH, Pang T, et al. Asia-Pacific Health 2020 and genomics without borders: co-production of knowledge by science and society partnership for global personalized medicine. Curr Pharmacogenomics Person Med 2011; 9(1): 1-5.
18. Veenstra D, Burke W. Pharmacogenomics and public health. Public Health Genomics 2009; 12(3): 131-3.
19. Bernstein A, Pulendran B, Rappuoli R. Systems vaccinomics: the road ahead for vaccinology. OMICS 2011; 15(9): 529-31.
20. Burke W, Khoury MJ, Stewart A, et al. Bellagio working group. The Path from Genome-Based Research to Population Health: Development of an International Public Health Genomics Network. Genet Med 2006; 8: 451-8.
21. Department of Health. Public health in England. Report of the Committee of Inquiry into the Future Development of the Public Health Function. (Cm 289.) London: HMSO, 1988.
22. Brand A, Knoppers BM, Ambrosino E. Public Health Genomics journal: adjusting the agenda to future needs. Public Health Genomics 2011; 14(3): 125-6.
23. Khoury MJ. Muin J. Khoury discusses the future of public health genomics and why it matters for personalized medicine and global health. Curr Pharmacogenomics Person Med 2009; 7(3): 158-63.
24. Kuehn BM. Genomics illuminates a deadly brain cancer. JAMA 2010; 303 (10): 925-7.
25. Ozdemir V, Rosenblatt DS, Warnich L, et al. Towards an ecology of collective innovation: Human Variome Project (HVP), Rare Disease Consortium for Autosomal Loci (RaDiCAL) and Data-Enabled Life Sciences Alliance (DELSA). Curr Pharmacogenomics Person Med 2011; 9(4): 243-51.
26. Schofield PN, Eppig J, Huala E, et al. Research funding. Sustaining the data and bioresource commons. Science 2010; 330(6004): 592-3.
27. Fisher E. Editorial overview: public science and technology scholars: engaging whom? Sci Eng Ethics 2011; 17(4): 607-20.
28. Fedoroff NV. The global knowledge society. Science 2012; 335(6068): 503.
29. Ozdemir V, Knoppers BM. From government to anticipatory governance. Responding to challenges set by emerging technologies and innovation. In: Governance for Health in the 21st Century. Kickbusch I. (Editor). New York: Springer 2012 (in press).
30. European Commission. EUR 22700-Science & Governance-Taking European knowledge society seriously. Luxembourg: Office for Official Publications of the European Communities, 2007.
31. Harrison P. Curiosity, forbidden knowledge, and the reformation of natural philosophy in early modern England. Isis 2001; 92(2): 265-90.
32. Tian Q, Price ND, Hood L. Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. J Intern Med 2012; 271(2): 111-21.
33. Lehoux P. Moving beyond our mutual ignorance. Or, how would engaging the public benefit the personalized medicine community? Curr Pharmacogenomics Person Med 2011; 9(2): 76-9.
34. Langley A, Denis JL. Beyond evidence: the micropolitics of improvement. BMJ Qual Saf 2011; 20(Suppl 1): i43-6.
35. Marris C, Rose N. Open engagement: exploring public participation in the biosciences. PLoS Biol 2010; 8(11): e1000549.
36. Lavis JN, Ross SE, Hurley JE, et al. Examining the role of health services research in public policymaking. Milbank Q 2002; 80: 125-54.
37. Bourdieu P. Outline of a theory of practice. Cambridge: Cambridge University Press 1977.
38. Bourdieu P, Wacquant L. An invitation to reflexive sociology. Chicago: University of Chicago Press 1992.
39. Nowotny H. Wish fulfillment and its discontents. EMBO Rep 2003; 4(10): 917-20.
40. Kickbusch I. Health governance: the health society. In: Health and Modernity: The Role of Theory in Health Promotion. McQueen DV, Kickbusch I, Potvin L, et al., Eds. New York: Springer 2007; pp. 144-61.
41. Ozdemir V, Someya T. A transdisciplinary forum for study of individual and population variability in response to health interventions and personalized medicine. Curr Pharmacogenomics Person Med 2009; 7(3): 146-8.